Neurology

Notably, donor hearts from those who underwent circulatory death were able to be preserved and analyzed in situ.

Access, diagnosis, and treatment for BIPOC patients suffering from migraines is yet another unflattering reflection of the lack of health equity in the United States.

As part of the approval condition, the FDA is requiring Sarepta Therapeutics to complete a clinical study to confirm the drug’s benefit in motor and physical functions.

Migraines can be a primary diagnosis or a symptom of an underlying medical or psychological condition.

Leqembi is an intravenous injection for the treatment of Alzheimer disease.

Standard prediction models that assess an individual’s risk of developing dementia and how to prevent it are limited in their ability to do so, showing high error rates and a higher chance of receiving a false-positive result, according to a recent study.

Heidi Finnes, PharmD, BCOP, FHOPA, addresses how the study data may impact the treatment of IDH1/2 mutating gliomas going forward.

Study evaluates the interaction between excessive salt intake and hypertension, cognitive dysfunction, and dementia.

Neuromyelitis optica spectrum disorder is an autoimmune disease characterized by severe attacks of optic neuritis and/or myelitis, leading to possible visual loss, paralysis, cognitive impairment, sensory deficits, bladder dysfunction, and even mortality.

Having more severe sleep apneas was associated with having lower brain volume in the medial temporal lobe area of the brain, which could suggest loss of brain cells.

Current standard of care gives 2 poor options to patients, neither of which cure grade 2 gliomas.

Pediatric drug development, which has a complex background and history, has fundamental catches based around how children are defined in the context of clinical studies.

Although an established standard of care for migraine prophylaxis exists, the current protocol is not without significant shortcomings.

Long-term data show that early treatment with ofatumumab decreased confirmed disability worsening in nearly all study patients with relapsing multiple sclerosis.

Brexpiprazole was associated with a statistically and clinically meaningful improvement in agitative behaviors caused by dementia compared to placebo.

Atogepant reduced mean monthly migraine days by more than 2 days compared to placebo in the ELEVATE trial.

Lack of awareness, or anosognosia, may be present up to 2 to 3 years before an Alzheimer dementia diagnosis is made.

Comorbidities and cognitive impairment worsen non-adherence to anti-seizure medications in older adults.

More than half of patients with Alzheimer disease administered donanemab showed a significantly reduced cognitive and functional decline.

Study shows eplontersen maintains a consistent and sustained treatment effect and reinforces its potential treating hereditary transthyretin-mediated amyloid polyneuropathy, which can lead to heart failure.

Session at the 2023 Asembia Summit notes that pharmacists play a particularly important role in the large multidisciplinary care team needed for Rett syndrome management.

Infants diagnosed with invasive Group B Streptococcus meningitis had an increased risk of developing epilepsy if the mother was of lower income.

Six weeks after infusion of GD2-CART01, 9 of 27 patients (33%) with relapsed or refractory high-risk neuroblastoma had a complete response or maintained a complete response.

Lowering blood pressure could be dangerous for people with normal blood pressure.

Clinicians are often focused on reducing brain damage after traumatic injury, but considering nutrition is an important component to healing.

Atogepant (Qulipta; AbbVie) is the first and only oral calcitonin gene-related peptide receptor antagonist to gain FDA approval for the prevention of episodic and chronic migraine.

The efficacy and tolerability of rizatriptan for acute migraine treatment has been well established.

Pharmacists are crucial in supporting patients with attention-deficit hyperactivity disorder as shortages of Adderall continue.

As more drugs gain coverage, decision-makers will need to more accurately diagnose Alzheimer disease, especially in the community setting.

The implementation of genetic testing for patients prescribed medications associated with progressive multifocal leukoencephalopathy is likely to improve safety outcomes.